



AtriCure Receives CE Mark for the AtriClip® PRO2 Device

June 29, 2016

CE Mark brings the increased functionality of the AtriClip PRO2 device to the European market for use in managing the left atrial appendage; product was launched in the U.S. in April 2016

MASON, Ohio--(BUSINESS WIRE)--Jun. 29, 2016-- [AtriCure, Inc. \(Nasdaq: ATRC\)](#), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that it has received CE Mark for the AtriClip PRO2 Left Atrial Appendage (LAA) Exclusion System, which offers increased functionality to occlude the LAA during minimally-invasive surgical (MIS) procedures. The device was previously launched in April 2016 with FDA 510(k) Clearance in the United States.

"We are excited to bring the AtriClip PRO2 device to the European market," said Michael Carrel, President and CEO of AtriCure. "The US launch has been well received by our customers and we're looking forward to the continued growth of the AtriClip franchise."

The addition of the AtriClip PRO2 device has expanded the left atrial appendage product offerings and now provides an ambidextrous locking and trigger-style clip closing mechanism, handle-based active articulation levers, and a hoopless end effector. These features have improved the ease of use and time it takes to manage the left atrial appendage.

For more information about the AtriClip franchise or left atrial appendage management visit our website at <http://www.atricure.com/atrial-occlusion>.

About AtriCure, Inc.

AtriCure, Inc. is a medical device company providing innovative atrial fibrillation (Afib) solutions designed to produce superior outcomes that reduce the economic and social burden of atrial fibrillation. AtriCure's Synergy™ Ablation System is the first and only surgical device approved for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures. AtriCure's AtriClip® left atrial appendage management (LAAM) exclusion device is the most widely sold device worldwide that is indicated for the occlusion of the left atrial appendage. The company believes cardiothoracic surgeons are adopting its ablation and LAAM devices for the treatment of Afib and reduction of Afib related complications such as stroke. AtriCure recently acquired nContact, a leader in minimally invasive technology for epicardial ablation. nContact's mission is to transform the underserved arrhythmia population through a multidisciplinary epicardial-endocardial ablation approach. Afib affects more than 33 million people worldwide. For more information visit AtriCure.com or follow us on Twitter @AtriCure.

View source version on businesswire.com: <http://www.businesswire.com/news/home/20160629005225/en/>

Source: AtriCure, Inc.

AtriCure, Inc.
Valerie Storch-Willhaus
Media Relations
Director, Corporate Marketing and Communications
612-605-3311
vstorch-willhaus@atricure.com
or
Andy Wade
Investor Relations
Senior Vice President and Chief Financial Officer
513-755-4564
awade@atricure.com